Additional posters showcase the ability of cytoDRiVE regulation technology to potentially unlock the therapeutic window of potent cytokines and broaden the reach of armored cell therapies mbIL12 ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback